
Tessier et al. Figure Supplementary 1



Supplementary Figure 1.

(a) Immunofluorescence analysis of mESCs showing arsenic-enhanced PML NBs and endogenous SUMO1 (lef) or SUMO2 (right) recruitment into PML NBs. (b) Confocal analysis of endogenous mouse PML in leukemic bone marrow from APL mice, showing fast PML NBs reorganization during arsenic kinetic. Mean intensity Z-section projections are shown. Scale bar: 5 μm. (c) His-pulldown from liver as indicated, showing increase in PML sumoylation and/or expression upon arsenic and/or pI:C injection, and free His6-HASUMO1. (d) Confocal analyses of liver cryo-sections from His6-HA-SUMO1 mice showing increase endogenous PML, SUMO1 or SUMO2/3 at PML NBs upon the indicated treatment. (e) Quantification of the SUMO2/3 conjugates after His-pulldown from 0.5h-arsenic-treated mESCs relative to paired untreated cells (Fig. 1d right), Mean +/- s.d. of (n=9) independent experiments. **p<0.01, *****p<0.0001 two-tailed Wilcoxon-Mann-Whitney test. (f) Pulldown of His10-SUMO2 conjugates from spleen of His10-SUMO2 or control APL mice, as in e, showing increased sumoylation upon arsenic-induced PML NBs reassembly. Inputs indicate unconjugated SUMO2 in APL. Representative of n=3 independent experiments with 2 mice each. (g) Quantification of the conjugated SUMO1 or SUMO2/3 in liver after His-pulldown and related to paired untreated mice (Fig. 1f). Data represent n >3 independent experiments, Error bars represent s.d., ** p<0.01; *** p<0.001, Fisher's exact test. (h) His10-SUMO2 conjugates, pulldown from mESCs stably expressing His10-SUMO2 or the all K/R mutant version, and immunoblotted with anti-SUMO2/3 and anti-PML. Red arrows underline arsenic-increased sumoylation in His10-SUMO2-expressing cells only.